Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Clinical Diagnostics and Pathology in Gynecological Cancer
share announcement

Clinical Diagnostics and Pathology in Gynecological Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 5838

Special Issue Editor

Dr. Emmanouil Kalampokas

E-Mail Website
Guest Editor
2nd Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece
Interests: endometrial cancer; ovarian cancer; cervical cancer; endoscopy in gynecological oncology; colposcopy

Special Issue Information

Dear Colleagues, 

The incidence of gynecological cancers is rising, and healthcare professionals need to be informed about the latest data regarding the constant developments in the field of its management. Wide-scale genome studies have contributed to a better understanding of carcinogenesis in gynecological cancers and the integration of molecular biomarkers into international risk stratification systems. Additionally, innovative therapeutic strategies are being developed, both surgical and medical, such as the implementation of radical surgery in the management of ovarian cancer and immunotherapeutic agents that target selective molecules.

This Special Issue aims to provide an up-to-date and detailed picture in this area by gathering contributions that cover all aspects related to the field of Gynecological Oncology, answering fundamental questions (e.g., the diagnosis and pathology of cancers and pre-invasive disease) from recent advancements in both surgery and research, to clinical trials and applications (e.g., the use of sentinel lymph nodes in gynecological cancers, the molecular categorization of endometrial cancers, radical surgery in ovarian cancer and the use of immunotherapy).

The primary goals of this Special Issue, entitled “Clinical Diagnostics and Pathology in Gynecological Cancer” are to describe new and established diagnostic and treatment modalities; to discuss approaches to complex clinical situations; and to review new research developments in the field of Gynecological Oncology.

Dr. Emmanouil Kalampokas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • ovarian cancer
  • cervical cancer
  • vulval cancer
  • pre-invasive disease
  • immunotherapy and new agents in the treatment of gynecological cancers
  • new diagnostic modalities in gynecological cancers
  • endoscopy in gynecological oncology
  • rare gynecological cancers

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 586 KiB  
Article
Improving the Quality of Care for Cancer Patients through Oncological Second Opinions in a Comprehensive Cancer Center: Feasibility of Patient-Initiated Second Opinions through a Health-Insurance Service Point
by Carla E. Schulmeyer, Matthias W. Beckmann, Peter A. Fasching, Lothar Häberle, Henriette Golcher, Frank Kunath, Bernd Wullich and Julius Emons
Diagnostics 2023, 13(21), 3300; https://doi.org/10.3390/diagnostics13213300 - 25 Oct 2023
Viewed by 792
Abstract
Background: To improve the quality and cost-effectiveness of care, cancer patients can obtain a second medical opinion on their treatment. Validation of the diagnostic procedure (e.g., imaging), diagnosis, and treatment recommendation allows oncological therapy to be applied in a more targeted way, optimizing [...] Read more.
Background: To improve the quality and cost-effectiveness of care, cancer patients can obtain a second medical opinion on their treatment. Validation of the diagnostic procedure (e.g., imaging), diagnosis, and treatment recommendation allows oncological therapy to be applied in a more targeted way, optimizing interdisciplinary care. This study describes patients who received second opinions at the Comprehensive Cancer Center for Erlangen–Nuremberg metropolitan area in Germany over a 6-year period, as well as the amount of time spent on second-opinion counseling. Methods: This prospective, descriptive, single-center observational study included 584 male and female cancer patients undergoing gynecological, urologic, or general surgery who sought a second medical opinion. The extent to which the first opinion complied with standard guidelines was assessed solely descriptively. Results: The first opinion was in accordance with the guidelines and complete in 54.5% of the patients, and guideline compliant but incomplete in 13.2%. The median time taken to form a second opinion was 225 min, and the cancer information service was contacted by patients an average of eight times. Conclusions: The initial opinion was guideline compliant and complete in every second case. Without a second opinion, the remaining patients would have been denied a guideline-compliant treatment recommendation. Obtaining a second opinion gives patients an opportunity to receive a guideline-compliant treatment recommendation and enables them to benefit from newer, individualized therapeutic approaches in clinical trials. Establishing patient-initiated second opinions via central contact points appears to be a feasible option for improving guideline compliance. Full article
(This article belongs to the Special Issue Clinical Diagnostics and Pathology in Gynecological Cancer)
►▼ Show Figures

Figure 1

13 pages, 2162 KiB  
Article
Chemerin and Chemokine-like Receptor 1 Expression in Ovarian Cancer Associates with Proteins Involved in Estrogen Signaling
by Florian Weber, Susanne Schueler-Toprak, Christa Buechler, Olaf Ortmann and Oliver Treeck
Diagnostics 2023, 13(5), 944; https://doi.org/10.3390/diagnostics13050944 - 2 Mar 2023
Cited by 1 | Viewed by 3054
Abstract
Chemerin, a pleiotropic adipokine coded by the RARRES2 gene, has been reported to affect the pathophysiology of various cancer entities. To further approach the role of this adipokine in ovarian cancer (OC), intratumoral protein levels of chemerin and its receptor chemokine-like receptor 1 [...] Read more.
Chemerin, a pleiotropic adipokine coded by the RARRES2 gene, has been reported to affect the pathophysiology of various cancer entities. To further approach the role of this adipokine in ovarian cancer (OC), intratumoral protein levels of chemerin and its receptor chemokine-like receptor 1 (CMKLR1) were examined by immunohistochemistry analyzing tissue microarrays with tumor samples from 208 OC patients. Since chemerin has been reported to affect the female reproductive system, associations with proteins involved in steroid hormone signaling were analyzed. Additionally, correlations with ovarian cancer markers, cancer-related proteins, and survival of OC patients were examined. A positive correlation of chemerin and CMKLR1 protein levels in OC (Spearman’s rho = 0.6, p < 0.0001) was observed. Chemerin staining intensity was strongly associated with the expression of progesterone receptor (PR) (Spearman´s rho = 0.79, p < 0.0001). Both chemerin and CMKLR1 proteins positively correlated with estrogen receptor β (ERβ) and estrogen-related receptors. Neither chemerin nor the CMKLR1 protein level was associated with the survival of OC patients. At the mRNA level, in silico analysis revealed low RARRES2 and high CMKLR1 expression associated with longer overall survival. The results of our correlation analyses suggested the previously reported interaction of chemerin and estrogen signaling to be present in OC tissue. Further studies are needed to elucidate to which extent this interaction might affect OC development and progression. Full article
(This article belongs to the Special Issue Clinical Diagnostics and Pathology in Gynecological Cancer)
►▼ Show Figures

Figure 1

12 pages, 683 KiB  
Article
Clinical and Pathological Profiles of Vertebral Bone Metastases from Endometrial Cancers: Evidence from a Twenty-Year Case Series
by Stefano Bandiera, Francesca Salamanna, Veronica Borsari, Deyanira Contartese, Marco Bontempi, Matilde Tschon, Giovanni Tosini, Stefano Pasini, Silvia Terzi, Milena Fini and Alessandro Gasbarrini
Diagnostics 2022, 12(12), 2941; https://doi.org/10.3390/diagnostics12122941 - 25 Nov 2022
Viewed by 1318
Abstract
Patients with endometrial cancer (EC) frequently have metastases to lungs, extra-pelvic nodes, and liver. Although an uncommon occurrence, cases of EC metastasis to bone, prevalently in vertebral bone, have also been reported. The objective of this study was to analyze clinical and pathological [...] Read more.
Patients with endometrial cancer (EC) frequently have metastases to lungs, extra-pelvic nodes, and liver. Although an uncommon occurrence, cases of EC metastasis to bone, prevalently in vertebral bone, have also been reported. The objective of this study was to analyze clinical and pathological profiles of patients with EC metastatic to vertebral bone. We carried out a retrospective case series on surgically treated patients for this pathology. From 2001 to 2021, out of 775 patients with bone metastasis, 1.6% had bone metastasis from EC. The median time between the diagnosis of primary tumor and that of bone metastases was 31.5 months. Solitary bone lesion was present in 7 patients and lumbar vertebrae were the segments most affected. Pathological fractures in 46.2% of patients and spinal pain in all were present. In terms of location, 46.2% of bone metastases resided within the anterior section of the vertebra, while the remaining presented an extension within the anterior and posterior sections, with 46.1% of cases showing an extradural extra-osseous extension and paraspinous envelope. Median survival after diagnosis of bone metastasis was 11.5 months. Vertebral bone metastasis in EC is a rare phenomenon, with severe prognosis. An in-depth understanding of this topic may guide future management and treatment decisions, thus improving life expectancy and quality. Full article
(This article belongs to the Special Issue Clinical Diagnostics and Pathology in Gynecological Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop